emilumenib   Click here for help

GtoPdb Ligand ID: 13617

Synonyms: DS-1594a | DS-1594b
PDB Ligand
Compound class: Synthetic organic
Comment: Emilumenib (DS-1594) is an orally available small-molecule menin inhibitor [1]. It binds to the nuclear protein menin (MEN1) and prevents its interaction with menin-mixed lineage leukemia (MLL; KMT2A, lysine methyltransferase 2A), as a mechanism to disrupt proleukemogenic signalling via the menin-KMT2A complex in acute leukemias with KMT2A rearrangements.
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 9
Hydrogen bond donors 2
Rotatable bonds 10
Topological polar surface area 128.7
Molecular weight 574.62
XLogP 2.54
No. Lipinski's rules broken 1

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

SMILES / InChI / InChIKey
Click here for help
Canonical SMILES CN([C@H]1C[C@H](C[C@H]1O)NCC2=CC=C(C=C2)C3=CC(=C(N=N3)OC)OC)C4=NC=NC5=C4C=C(CC(F)(F)F)S5
Isomeric SMILES CN([C@H]1C[C@H](C[C@H]1O)NCC2=CC=C(C=C2)C3=NN=C(C(=C3)OC)OC)C4=C5C=C(SC5=NC=N4)CC(F)(F)F
InChI InChI=1S/C27H29F3N6O3S/c1-36(24-19-10-18(12-27(28,29)30)40-26(19)33-14-32-24)21-8-17(9-22(21)37)31-13-15-4-6-16(7-5-15)20-11-23(38-2)25(39-3)35-34-20/h4-7,10-11,14,17,21-22,31,37H,8-9,12-13H2,1-3H3/t17-,21+,22-/m1/s1
InChI Key FFHYBSANKGPTCW-VOQZNFBZSA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

No information available.
Summary of Clinical Use Click here for help
DS-1594 was advanced to clinical evaluation for efficacy in acute leukemias with KMT2A or nucleophosmin 1 (NPM1) rearrangements.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT04752163 DS-1594b With or Without Azacitidine, Venetoclax, or Mini-HCVD for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia Phase 1/Phase 2 Interventional M.D. Anderson Cancer Center